Abcam Plc (LON:ABC) had its target price hoisted by Numis Securities Ltd from GBX 1,116 ($14.41) to GBX 1,200 ($15.50) in a research report issued to clients and investors on Tuesday. The brokerage presently has an “add” rating on the stock. Numis Securities Ltd’s target price points to a potential upside of 13.64% from the stock’s current price.
A number of other research firms have also weighed in on ABC. Peel Hunt reaffirmed a “hold” rating and set a GBX 750 ($9.69) price objective on shares of Abcam Plc in a research report on Friday, August 18th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,100 ($14.21) price objective on shares of Abcam Plc in a research report on Monday. Panmure Gordon reaffirmed a “sell” rating on shares of Abcam Plc in a research report on Monday. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating and set a GBX 864 ($11.16) price objective on shares of Abcam Plc in a research report on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. Abcam Plc currently has an average rating of “Hold” and a consensus target price of GBX 914 ($11.80).
Shares of Abcam Plc (LON ABC) opened at 1079.00 on Tuesday. The company’s market cap is GBX 2.18 billion. The company’s 50-day moving average price is GBX 1,049.86 and its 200 day moving average price is GBX 950.84. Abcam Plc has a one year low of GBX 725.50 and a one year high of GBX 1,090.00.
Abcam Plc Company Profile
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with MarketBeat.com's FREE daily email newsletter.